News for hackers. Stuff that matters.
Re:Ozempic Threatens Profits at Food and Beverage Makers Wor... by wwasilev on Saturday October 21, 2023 @08:08PM (#37971665)
This is just getting started. VKTX just reported phase 1 results of their GLP1/GIP dual agonist. It appears effective in reducing liver fat (NASH), plasma lipips and weight. The side effects were mild to moderate.

TERN and GPCR are also in the game.

There are no comments on this comment yet.